Latest news with #AtroposEvidenceNetwork
Business Wire
2 days ago
- Health
- Business Wire
Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with Novartis. Through this strategic collaboration, Atropos Health will build, train and evaluate multiple models to help streamline identification of people with a rare disease who have not yet been diagnosed, ultimately reducing time from symptom reporting to testing, diagnosis and treatment. The collaboration will specifically focus on paroxysmal nocturnal hemoglobinuria (PNH), a rare, serious blood disorder. Adults with PNH often experience lengthy diagnostic delays—many wait over a year, and some more than five—because the disease is rare and presents varied symptoms affecting multiple organs. 1,2 As a part of this collaboration, Atropos Health has developed an initial AI model for finding potential patients with PNH who have not yet been diagnosed, aimed to save critical time for both patients and providers by helping health systems accelerate appropriate diagnosis. The AI model is now available for integration into health systems. 'Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. 'The accuracy of the models reduces the guesswork and patients who are able to get testing sooner provides a potentially life-changing experience. For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction.' The goal of the strategic collaboration is to build and publish patient-finding models aimed at reducing time from initial symptoms to testing, diagnosis and treatment. The models created by Atropos Health in connection with this collaboration will be implemented across health system members of the Atropos Evidence Network and be seamlessly integrated at the point of care to improve the provider and patient experience. Through this collaboration, Atropos Health will build models trained on real-world data (RWD) from the Atropos Evidence™ Network, which includes GENEVA OS ®. 'At Novartis, we are committed to delivering meaningful impact for patients. Accelerating diagnosis and treatment through AI and machine learning has the power to significantly improve patient outcomes by enabling faster access to appropriate care,' said Rodney Gillespie, Head of Oncology, Novartis US. 'Our collaboration with Atropos Health to develop an AI model for identifying PNH embodies this commitment as it advances precision health, potentially enabling earlier diagnosis and timely care, reducing delays that can greatly affect patients' lives.' About paroxysmal nocturnal hemoglobinuria (PNH) PNH is a rare, chronic and serious complement-mediated blood disorder 3. People with PNH have an acquired mutation in some of their hematopoietic stem cells (which are located in the bone marrow and can grow and develop into red blood cells [RBCs], white blood cells and platelets) that causes them to produce RBCs that are susceptible to premature destruction by the complement system. 4 It is estimated that approximately 10-20 people per million worldwide live with PNH. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. 5,6 Today's announcement follows Atropos Health's AI model training capabilities released earlier this year. Atropos Evidence Network membership benefits include the ability to leverage the network to deliver AI models to clinicians. Atropos Health is collaborating with Arcadia to help leading healthcare organizations deliver the latest care protocols and advanced precision medicine at scale. The partnership enables healthcare providers to accelerate clinical decision-making with actionable, AI-powered insights at the point of care using the combination of real-world evidence (RWE) and longitudinal patient records to improve outcomes and drive high-value, low-cost care. Healthcare organizations are also engaged with Atropos Health on leveraging AI for precision medicine, and building MOTOR, CLMBR and Foundation models on the Atropos Evidence Network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. _________________________ 1 Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8. PMID: 33356781; PMCID: PMC10408416 2 Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. Hematol Rep. 2018 Mar 29;10(1):7523. doi: 10.4081/hr.2018.7523. PMID: 29721255; PMCID: PMC5907647. 3 Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341-348. 4 Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. 5 Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. 6 Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3-11. Expand
Business Wire
12-06-2025
- Business
- Business Wire
Atropos Health and Kythera Labs Partner to Expand Access to Real-World Data to Advance Oncology
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in generating real-world evidence (RWE) from high-quality healthcare data today announced a partnership with Kythera Labs, a leading healthcare data and technology company, adding to the growing number of datasets and use cases for the Atropos Evidence™ Network including oncology. This is the first step in a multiyear agreement between the two companies committed to turning data and knowledge of molecular biology in health and disease into meaningful health outcomes. With the Kythera Labs collaboration, the Atropos Evidence Network continues to expand, adding the high-quality datasets needed to generate actionable insights. By utilizing Atropos Health's Real World Data Score® (RWDS) & Real World Fitness Score® (RWFS), users can select the dataset that is the most suitable to answer each question. Kythera Labs' Oncology Event asset is a rich, high-fidelity dataset that provides comprehensive insights into the oncology care continuum, including patient interactions, treatment decisions, and provider engagements. Built from Kythera Labs' Remastered Source Data, the Oncology Event asset utilizes Kythera Labs' dynamic common data model and proprietary methodologies to ensure accuracy and depth. Through Atropos Evidence Network, organizations can quickly access actionable insights that support faster and more confident decisions in oncology research, clinical trials, and patient care. 'Growing the multimodal oncology network increases the opportunity for Atropos Evidence Network members to find more 'fit-for-purpose' data' said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. 'Together with Kythera Labs, we will better enable healthcare organizations to accelerate and improve clinical decision making, clinical research productivity and clinical trial site selection and recruitment with novel evidence-based insights.' The Atropos Evidence Network creates a market for data holders to expand the reach of these de-identified assets to a broader audience. Data contributors receive transparent, analytically driven feedback on usage and their own data quality and strengths. Atropos Health is the connection between real-world evidence (RWE) and actionable clinical analytics. With the addition of Kythera Lab's purpose-built, remastered Real World Data, comprehensive, enriched insights into the full oncology care continuum, including patient interactions, provider engagements, and treatment nuances, will help spur innovation and optimize patient care strategies. "At Kythera Labs, we are committed to closing the gaps between R&D and care delivery, moving insights from the clinical bedside to the research bench,' said Jeff McDonald, CEO and co-founder of Kythera Labs. 'Partnerships like this are integral to making progress within the field of oncology. By collaborating with Atropos Health and providing access to our enriched and analytics-ready data assets, we hope to help Evidence Network users reach answers faster and more cost-efficiently.' The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model, forming secure, cloud-based connections between healthcare data proprietors and clinical insight seekers across the healthcare ecosystem. De-identified data doesn't change hands - institutional members of the network, such as a physician or researcher, can pose clinical questions to a variety of datasets. Within 48 hours, the user receives a novel retrospective observational study in response. About Atropos Health Atropos Health is the developer of GENEVA OS™ , the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. About Kythera Labs Kythera Labs is a data technology company that unifies data science and data technology to enable higher fidelity in healthcare data for Healthcare and Life Sciences organizations. Our multi-source data captures over 310M de-identified unique individuals and our technology is built for RWD users to integrate, access, analyze and find answers. Learn more at or follow Kythera Labs on LinkedIn.
Business Wire
30-05-2025
- Business
- Business Wire
Atropos Health Continues Commitment to Advancements in Oncology with Addition of Key Personnel
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the leader in generating personalized real-world evidence (RWE) from real-world clinical data, today announced key personnel and product features enhancing their Oncology solutions. The company previously announced the expansion of the Oncology MultiModal Network in the Atropos Evidence™ Network with the addition of Ontada's community oncology real-world data (RWD). In addition to the growth of the Atropos Evidence Network, Atropos Health is also adding key personnel to enhance the oncology focus: Cory D. Wiegert joins as Chief Operating Officer, bringing over 25 years of experience leading innovation and product development in enterprise software and healthcare IT including the launch of a cloud-based, AI-driven decision platform. His extensive background also includes overseeing the industry's largest dataset for value-based, specialty care at Integra Connect and leadership roles at CancerLinQ, IBM Watson Health, and Siebel Systems. Dr. Morgan Cheatham joins the Atropos Health Board of Directors as a Board Observer bringing extensive expertise as Partner and Head of Healthcare and Life Sciences for Breyer Capital, where he leads investments across various sectors, including AI. Previously at Bessemer Venture Partners, he spearheaded early-stage investments in companies like Abridge and Hinge Health. Cheatham is also pursuing a fellowship in Clinical Genetics at Harvard/Boston Children's, serves on the Editorial Team for NEJM AI and Board Director for Coalition for Health AI, and has published research on clinical AI and genetic medicine in leading journals. Jason Jones heads Data Science at Atropos Health bringing extensive experience as the former Chief Data Scientist at Health Catalyst and a Research Scientist and VP at Kaiser Permanente. His background also includes significant roles in medical informatics at Intermountain Healthcare and leadership positions at Bayer HealthCare and UnitedHealth Group. "We're investing heavily in both product and personnel when it comes to applying RWE to oncology practice and research and development," said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "Bringing on additional Oncology-specific expertise signals our further investment and commitment to advancing life saving treatments in oncology. " Along with the Ontada partnership, existing partner Norstella is now also an additional source of RWD for the Oncology MultiModal network in the Atropos Evidence Network, further enhancing the market leading federated oncology evidence network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Business Wire
28-04-2025
- Business
- Business Wire
Atropos Health Expands Oncology MultiModal Network in the Atropos Evidence Network with Addition of Ontada
PALO ALTO, Calif.--(BUSINESS WIRE)-- Atropos Health, a leader in transforming clinical real-world data (RWD) into personalized real-world evidence (RWE) and insights, has announced a strategic collaboration with Ontada®, a McKesson business and leader in community oncology RWD, clinical education, and point-of-care technologies. This collaboration will enhance the use cases for clinicians, researchers, and healthcare leaders to design care protocols, advance precision medicine and develop new treatments in oncology. Atropos Health's automation tools generate evidence from a customer's own data, via the installation of GENEVA OS™ into customers' internal cloud data environment and the Atropos Evidence™ Network, the largest federated data network in healthcare with over 300 million patient records. As members run queries on the RWD in the Atropos Evidence Network, they have access to the right data for each question, evaluated by the Real-World Fitness Score®. "The demand for high-quality data in oncology is ever present," said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. "The Atropos Evidence™ Network, which will now include Ontada's RWD, includes benefits across the entire healthcare ecosystem. For health systems, the oncology multi-modal network contains the high quality RWD necessary to generate the RWE needed for high-stakes clinical decisions. This collaboration with Ontada will help life sciences organizations accelerate the rate at which RWE insights drive decision-making for drug discovery and development and ensure they are presented and acted upon, driving innovation and ultimately improving the lives of cancer patients." Ontada provides unique insights into the community oncology landscape, where approximately 85% of cancer patients are treated. Its proprietary database, iKnowMed®, is sourced in part from The US Oncology Network, a leading community oncology physician network. The US Oncology Network treats more than 1.4 million cancer patients annually. Ontada's RWD offers comprehensive insights throughout the patient journey and provides a unique view of community cancer care, representing data from more than 2.4 million patients across more than 80 tumor types. "Ontada and Atropos Health are committed to accelerating evidence generation to drive better outcomes for patients with cancer," said Christine Davis, President of Ontada. "This collaboration will empower life sciences organizations by enhancing their evidence-generation capabilities and supporting more effective clinical decision-making that can help to improve patient care." This collaboration comes on the heels of Atropos Health's recent announcement of Federated Nodal Deidentification Technology. The new technology will be added to the GENEVA OS™ platform, available to all Atropos Evidence™ Network members. Longitudinal patient records provide a more complete view of a patient journey. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
